Respiration; international review of thoracic diseases · 2025
Validation of the Telephone Version of S3-Non-Invasive Ventilation Questionnaire in Patients with Chronic Obstructive Pulmonary Disease.
СтатьяНаблюдательное исследованиеВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roseta Leonor, Viegas Pedro, Oliveira Maria João, Pais Mafalda, Nogueira Carla, Conde Sara, Castro Luísa, Jácome Cristina, Ribeiro Carla
Аннотация
INTRODUCTION: This study aimed to validate the telephone administration of the S3-non-invasive ventilation questionnaire (S3-NIV), a patient-reported outcome measure assessing the impact of NIV on patients' quality of life, in a Portuguese cohort of patients with chronic obstructive pulmonary disease (COPD) and chronic respiratory failure (CRF) under NIV.
METHODS: We conducted a prospective observational study with patients with COPD and CRF at a Portuguese tertiary hospital, including participants who completed both paper and telephone versions of the S3-NIV in randomized order within 10 days.
RESULTS: Internal consistency was good in both telephone and paper versions: S3-NIV-total (α = 0.78 and 0.74), S3-NIV-respiratory symptoms (α = 0.78 and 0.74), and S3-NIV-sleep and side effects (α = 0.68 and 0.62). Moderate to strong convergent validity was found (S3-NIV-total - rs = 0.75, S3-NIV-respiratory symptoms - rs = 0.73, S3-NIV-sleep and side effects - rs = 0.67). Relative reliability was good in all scores: S3-NIV-total (ICC 0.74 [95% CI 0.61; 0.83]), S3-NIV-respiratory symptoms (ICC 0.74 [95% CI 0.61; 0.83]), and S3-NIV-sleep and side effects (ICC 0.65 [95% CI 0.50; 0.77]). Bland-Altman plots demonstrated reasonable agreement, with most differences within acceptable limits and a minor bias.
CONCLUSION: The telephone-administered S3-NIV is a valid, reliable tool for assessing the impact of NIV on quality of life in patients with COPD, supporting its use in remote clinical settings.
METHODS: We conducted a prospective observational study with patients with COPD and CRF at a Portuguese tertiary hospital, including participants who completed both paper and telephone versions of the S3-NIV in randomized order within 10 days.
RESULTS: Internal consistency was good in both telephone and paper versions: S3-NIV-total (α = 0.78 and 0.74), S3-NIV-respiratory symptoms (α = 0.78 and 0.74), and S3-NIV-sleep and side effects (α = 0.68 and 0.62). Moderate to strong convergent validity was found (S3-NIV-total - rs = 0.75, S3-NIV-respiratory symptoms - rs = 0.73, S3-NIV-sleep and side effects - rs = 0.67). Relative reliability was good in all scores: S3-NIV-total (ICC 0.74 [95% CI 0.61; 0.83]), S3-NIV-respiratory symptoms (ICC 0.74 [95% CI 0.61; 0.83]), and S3-NIV-sleep and side effects (ICC 0.65 [95% CI 0.50; 0.77]). Bland-Altman plots demonstrated reasonable agreement, with most differences within acceptable limits and a minor bias.
CONCLUSION: The telephone-administered S3-NIV is a valid, reliable tool for assessing the impact of NIV on quality of life in patients with COPD, supporting its use in remote clinical settings.